OKYO highlights urcosimod data and May conference talks

OKYO Pharma is highlighting its eye disease program through upcoming scientific meetings and recent clinical data.

Rhea-AI Filing Summary

OKYO Pharma is highlighting its eye disease program through upcoming scientific meetings and recent clinical data. The CEO will present at Eyecelerator on May 1, 2026, and the Chief Scientific Officer will present Phase 2 data at the ARVO Annual Meeting in Denver in early May.

The company’s lead drug, urcosimod, is an investigational therapy for neuropathic corneal pain (NCP) and inflammatory eye diseases. It is the first therapy to receive an IND specifically for NCP and has Fast Track designation from the U.S. FDA. OKYO reports clinically meaningful pain reduction and quality-of-life improvement in an 18-patient randomized, placebo-controlled, double-masked Phase 2 NCP trial, and statistically significant results in an earlier 240-patient Phase 2 dry eye disease trial. OKYO plans to start a 150-patient Phase 2b/3 multiple-dose NCP study in the first half of the year.

Insights

Biopharma clinical development analyst

OKYO is advancing urcosimod for neuropathic corneal pain with supportive Phase 2 data and upcoming scientific visibility.

OKYO Pharma emphasizes its lead candidate urcosimod for neuropathic corneal pain (NCP), a debilitating eye condition with no FDA-approved therapies. The drug has an IND specifically for NCP and holds FDA Fast Track designation, underscoring regulatory recognition of the unmet need.

The company cites a randomized, placebo-controlled, double-masked Phase 2 NCP study in 18 patients showing clinically meaningful pain and quality-of-life improvement, plus an earlier 240-patient Phase 2 trial in dry eye disease with statistically significant endpoints. A planned 150-patient Phase 2b/3 NCP study could provide more robust efficacy and safety data once underway.

Presentations at Eyecelerator on May 1, 2026 and at the ARVO Annual Meeting in early May 2026 will share these findings with clinicians and researchers. Future disclosures on the design, conduct, and results of the planned Phase 2b/3 trial will shape understanding of urcosimod’s potential in NCP.

Key Figures

Eyecelerator presentation time: 2:10-2:15 PM MDT NCP Phase 2 patients: 18 patients Dry eye Phase 2 size: 240 patients +3 more

6 metrics

Eyecelerator presentation time 2:10-2:15 PM MDT CEO presentation on May 1, 2026 in Denver

NCP Phase 2 patients 18 patients Randomized, placebo-controlled, double-masked NCP trial

Dry eye Phase 2 size 240 patients Multi-center, double-masked, placebo-controlled dry eye trial

Planned Phase 2b/3 size 150 patients Planned multiple-dose NCP study to start in first half of year

Fast Track designation Granted by U.S. FDA For urcosimod in neuropathic corneal pain

IND status First IND specifically for NCP Urcosimod investigational therapy

Key Terms

neuropathic corneal pain (NCP), Fast Track designation, Investigational New Drug (IND), Phase 2b/3 multiple-dose study, +2 more

6 terms

neuropathic corneal pain (NCP) medical

"a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic eye pain caused by damage or abnormal signaling in the nerves of the cornea, producing burning, stinging, or painful sensitivity often without visible surface injury. It matters to investors because it creates demand for specialized diagnostics and long‑term treatments distinct from standard eye drops—think of it like phantom limb pain for the eye—making it a potential market for new therapies and medical devices.

Fast Track designation regulatory

"Urcosimod is the first investigational therapy to receive an IND specifically for the treatment of neuropathic corneal pain and has been granted Fast Track designation"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

Investigational New Drug (IND) regulatory

"Urcosimod is the first investigational therapy to receive an IND specifically for the treatment of neuropathic corneal pain"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

Phase 2b/3 multiple-dose study medical

"plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP"

G-protein coupled receptor medical

"Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor"

double-masked, placebo-controlled trial medical

"a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did OKYO (OKYO) announce in its latest Form 6-K?

OKYO announced leadership presentations at Eyecelerator and the ARVO Annual Meeting, highlighting clinical data for its investigational drug urcosimod in neuropathic corneal pain and dry eye disease, and reiterating plans for a larger Phase 2b/3 NCP study.

What is urcosimod and what conditions is OKYO (OKYO) targeting?

Urcosimod is a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor. OKYO is developing it as an investigational therapy for neuropathic corneal pain and inflammatory eye diseases, including dry eye disease, where it has already shown anti-inflammatory and pain-reducing activity.

What clinical results has OKYO (OKYO) reported for urcosimod in neuropathic corneal pain?

OKYO reports positive data from a randomized, placebo-controlled, double-masked Phase 2 trial in 18 neuropathic corneal pain patients. Urcosimod produced clinically meaningful pain reduction and quality-of-life improvement, supporting further development in this chronic, debilitating condition with no FDA-approved therapies.

What prior trial data does OKYO (OKYO) cite for urcosimod in dry eye disease?

The company cites an earlier 240-patient, multi-center, double-masked, placebo-controlled Phase 2 trial in dry eye disease. In that study, urcosimod demonstrated clear statistical significance across multiple endpoints, suggesting both anti-inflammatory and pain-reducing effects in ocular surface disease.

What future clinical plans for urcosimod does OKYO (OKYO) describe?

OKYO plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat neuropathic corneal pain in the first half of the year. This larger trial is intended to build on earlier Phase 2 results and provide more definitive efficacy and safety information.

When and where will OKYO (OKYO) present urcosimod data at upcoming conferences?

The CEO is scheduled to present at Eyecelerator in Denver on May 1, 2026, discussing unmet needs in corneal and anterior segment diseases. The Chief Scientific Officer will present first-in-human urcosimod neuropathic corneal pain data at the ARVO Annual Meeting in Denver between May 3-7, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/29/2026 - 07:00 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

April 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On April 29, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing CEO presentation at Eyecelerator and leadership participation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: April 29, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated April 29, 2026

4

Exhibit 99.1

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

	●	Robert J. Dempsey, MBA, Chief Executive Officer, to present at Eyecelerator
	●	Raj Patil, PhD, Chief Scientific Officer, to present at ARVO

London and New York, NY, April 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced CEO presentation at Eyecelerator and leadership participation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, Colorado.

Upcoming Scientific Conferences:

Eyecelerator: May 1, 2026

Denver, Colorado

Presentation Title: Addressing Unmet Needs in Corneal and Anterior Segment Diseases

Presentation Date/Time: Friday May 1, 2026, 2:10-2:15 PM MDT

Breakout: Anterior Segment, Room 401

Presenter: Robert J. Dempsey, Chief Executive Officer at OKYO Pharma

Moderators: Julie Schallhorn, MD, MS; Kuldev Singh, MD

ARVO Annual Meeting: May 3-7, 2026

Denver, Colorado

Presentation Title: First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients

Presentation Date/Time: Tuesday May 5, 2026, 3:30 PM to 5:15 PM MDT

Poster Presentation/Board: 3461/0044

Session Title: Corneal Neuropathy and Ocular Pain

Session Number: Number 366

Presenter: Raj Patil, PhD, Chief Scientific Officer at OKYO Pharma

ARVO’s Annual Meeting is the premier global gathering for eye and vision scientists, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions.

Urcosimod is the first investigational therapy to receive an IND specifically for the treatment of neuropathic corneal pain and has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

About Neuropathic Corneal Pain (NCP)

Neuropathic corneal pain (NCP) is a chronic, often debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases the face or head. It is thought to result from damage or dysfunction of corneal sensory nerves, often in combination with inflammatory processes, and may occur in patients with a range of underlying ophthalmic conditions. There are currently no FDA-approved therapies specifically for NCP, resulting in patients being treated with limited or no success using various topical and systemic medications in an off-label manner.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients. Urcosimod showed clear statistical significance in multiple endpoints in an earlier 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development, and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 18.2 KB
• EX-99 GRAPHIC 4.6 KB